{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-24-000156","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.926215+00:00","generated_at":"2026-05-30T08:15:57.536402+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Summit reports Q3 net loss $56.3M; ivonescimab HARMONi-2 shows 49% risk reduction vs Keytruda","bullets":["Cash and short-term investments $487M (vs $186.2M Dec 2023) after $235M private financing in Sep 2024.","GAAP net loss $56.3M ($0.08/share) vs $21.2M ($0.03/share) in Q3 2023; R&D spend $37.7M.","Ivonescimab in HARMONi-2 (NSCLC) reduced disease progression/death by 49% vs pembrolizumab (HR 0.51; p<0.0001).","HARMONi (2L+ EGFRm) enrollment complete; topline mid-2025. HARMONi-3 to expand to non-squamous; HARMONi-7 to start early 2025.","Phase II data at ESMO/WCLC showed 71.8% MPR in perioperative NSCLC, 84.6% ORR in MSS CRC, 72.4% ORR in TNBC."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-24-000156","json":"https://secwatch.observer/filing/0001599298-24-000156.json","markdown":"https://secwatch.observer/filing/0001599298-24-000156.md","text":"https://secwatch.observer/filing/0001599298-24-000156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000156/0001599298-24-000156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000156/smmt-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:15:57.536402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}